Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Antares Pharma (ATRS)

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 692,078
  • Shares Outstanding, K 163,226
  • Annual Sales, $ 63,550 K
  • Annual Income, $ -6,520 K
  • 60-Month Beta 0.92
  • Price/Sales 6.52
  • Price/Cash Flow N/A
  • Price/Book 16.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.00
  • Number of Estimates 4
  • High Estimate 0.00
  • Low Estimate 0.00
  • Prior Year 0.04
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.14 +2.42%
on 01/06/20
4.90 -13.47%
on 12/18/19
-0.47 (-9.98%)
since 12/17/19
3-Month
3.22 +31.68%
on 10/31/19
5.13 -17.35%
on 12/03/19
+0.78 (+22.54%)
since 10/17/19
52-Week
2.60 +63.08%
on 04/18/19
5.13 -17.35%
on 12/03/19
+1.22 (+40.40%)
since 01/17/19

Most Recent Stories

More News
Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. Tykot is a seasoned corporate and business development...

EGRX : 58.97 (-0.97%)
ATRS : 4.24 (-4.50%)
Antares Pharma Social Media Campaign for XYOSTED(R) Wins MarCom Platinum Award

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") ("the Company") today announced that the Company's social media campaign for XYOSTED, has been honored with a 2019 MarCom Platinum Award. The award is the...

ATRS : 4.24 (-4.50%)
Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31 Annual Piper Jaffray Healthcare Conference on Tuesday December 3,...

ATRS : 4.24 (-4.50%)
REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. ("Idorsia") (SIX: IDIA) to develop a novel, drug-device product...

ATRS : 4.24 (-4.50%)
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. ("Idorsia") (SIX: IDIA) to develop a novel, drug-device product...

ATRS : 4.24 (-4.50%)
Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday November 20,...

ATRS : 4.24 (-4.50%)
Antares Pharma: 3Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported third-quarter net income of $1 million, after reporting a loss in the same period a year earlier.

ATRS : 4.24 (-4.50%)
Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

Record Quarterly Revenue of $34.3 Million - Earnings Per Share of $0.01

ATRS : 4.24 (-4.50%)
Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet(TM) Needle-Free Delivery System

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares" or "Company") today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals ("Ferring") in connection with the previously...

ATRS : 4.24 (-4.50%)
Antares Pharma to Report Third Quarter 2019 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2019 financial results and recent operating progress before the market opens on Tuesday, November 5, 2019. Management...

ATRS : 4.24 (-4.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ATRS with:

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Key Turning Points

2nd Resistance Point 4.55
1st Resistance Point 4.39
Last Price 4.24
1st Support Level 4.16
2nd Support Level 4.09

See More

52-Week High 5.13
Last Price 4.24
Fibonacci 61.8% 4.16
Fibonacci 50% 3.87
Fibonacci 38.2% 3.57
52-Week Low 2.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar